Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies

• Published in: Brachytherapy Vol. 22; no. 5; pp. 630 - 639
• Main Authors: McAlarnen, Lindsey A., Small, Christina, Tostrud, Lauren, Pan, Amy Y., Erickson, Beth, Bedi, Meena, Bradley, William H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2023
• Subjects: Anticoagulants - therapeutic use; Anticoagulation; Brachytherapy - methods; Cervical cancer; Female; Genital Neoplasms, Female - radiotherapy; Gynecologic malignancies; Hemorrhage; Humans; Inpatients; Interstitial brachytherapy; Neoplasm Recurrence, Local - drug therapy; Pharmacologic prophylaxis; Postoperative Complications - prevention & control; Retrospective Studies; Risk Factors; Venous thromboembolism; Venous Thromboembolism - drug therapy; Venous Thromboembolism - epidemiology; Venous Thromboembolism - prevention & control; Pharmacologic prophylaxis; Anticoagulation; Gynecologic malignancies; Cervical cancer; Venous thromboembolism; Interstitial brachytherapy
• ISSN: 1538-4721; 1873-1449
• DOI: 10.1016/j.brachy.2023.06.002

Brachytherapy irradiation carries risks of both bleeding and venous thromboembolism (VTE). No screening or management recommendations for VTE in this setting have been developed. Our study aims to understand the incidence of VTE, compile published anticoagulation guidelines, and call for future guidelines to address thromboprophylaxis in this population. A retrospective, single institution study of patients undergoing brachytherapy irradiation between 2012 and 2022 was undertaken. We analyzed 2 cohorts: 87 patients undergoing brachytherapy with an inpatient admission, and 66 patients assessed for risk of VTE or bleeding after discharge from an inpatient admission for brachytherapy. Caprini risk scores were calculated for each patient, and statistical analyses were performed. Eighty-seven patients were included, and 25% had a VTE diagnosis. Forty-seven (54%) of patients included underwent brachytherapy as definitive treatment of cervical cancer, and 16 (18%) received brachytherapy irradiation to treat recurrent endometrial cancer. In the cohort of 66 patients assessed for risk of VTE or bleeding after brachytherapy discharge, 23 (34.8%) were discharged with thromboprophylaxis, and 43 (65.2%) were discharged without thromboprophylaxis. None of the patients discharged on thromboprophylaxis were diagnosed with a VTE within 90 days of discharge after brachytherapy, whereas 3 of 43 (7%) discharged without thromboprophylaxis were diagnosed with a VTE, OR and 95% CI: 0.25 (0.01–5.29), p = 0.37. Of the 23 patients discharged on thromboprophylaxis, 1 was readmitted for bleeding OR and 95% CI: 5.8 (0.22–155.18), p = 0.29. The median Caprini score was 11. VTE is a common occurrence in patients undergoing brachytherapy. Patients undergoing brachytherapy irradiation who require inpatient admission represent a unique population, and specialty organizations should develop consensus recommendations to address these clinical challenges.